IP Library › Granted Patent US 10,098,848
Granted Patent B2
US 10,098,848 · App. 15/346,079 · Granted Oct 16, 2018

Inositol-containing comestible units and methods of treatment using the same

Inventor: Richard Louis Price (Suffern, NY)
A61K31/047A21D2/181A21D13/08A23L33/125A61K9/0056A61K31/165A61K31/4168A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,848
App. No.
15/346,079
Granted
Oct 16, 2018
Kind
B2
Abstract

A method for treating a patient having one or more of anxiety, hypersensitivity, restricted areas of interest, repetitive behaviors, irritability and emotional lability, or otherwise requiring a calming effect, is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol.

Claims (17)

1. A method for treating a patient, the method comprising: administering to the patient a therapeutically effective amount of inositol, wherein the therapeutically effective amount of inositol is at least 12,000 mg per day and the therapeutically effective amount of inositol is cumulatively provided in a plurality of inositol-containing comestible units per day, wherein the inositol-containing comestible units are prepared in a cooking or baking process wherein the units are heated in an oven environment that is set at least 300° F. or higher for at least eight minutes, wherein each comestible unit comprises a predetermined amount of inositol, the predetermined amount of inositol being from 1,500 to 6,000 mg of inositol, wherein the method is effective in treating one or more symptoms, whether or not such symptoms are rooted in an underlying psychiatric disorder or neurological disorder, wherein the symptoms are selected from the group consisting of: anxiety, hypersensitivity, restricted areas of interest, repetitive behaviors, irritability and emotional lability.

2. The method of claim 1 , wherein the predetermined amount of inositol is selected from an amount consisting of about: 1,500 mg, 1,600 mg, 1,700 mg, 1,800 mg, 1,900 mg, 2,000 mg, 2,100 mg, 2,200 mg, 2,300 mg, 2,400 mg, 2,500 mg, 2,600 mg, 2,700 mg, 2,800 mg, 2,900 mg, 3,000 mg, 3,100 mg, 3,200 mg, 3,300 mg, 3,400 mg, 3,500 mg, 3,600 mg, 3,700 mg, 3,800 mg, 3,900 mg, 4,000 mg, 4,100 mg, 4,200 mg, 4,300 mg, 4,400 mg, 4,500 mg, 4,600 mg, 4,700 mg, 4,800 mg, 4,900 mg, 5,000 mg, 5,100 mg, 5,200 mg, 5,300 mg, 5,400 mg, and 5,500.

3. The method of claim 1 , wherein the predetermined amount of inositol is from 3,000 to 6,000 mg of inositol.

4. The method of claim 1 , wherein the plurality of inositol-containing comestible units are selected from the group consisting of: cookies, brownies, pastries, doughnuts, graham crackers, cakes, chocolates, cereal bars, pies, wafers, muffins and cupcakes.

5. The method of claim 1 , wherein the plurality of inositol-containing comestible units are cookies, wherein each cookie contains from 2,500 to 4,500 mg of inositol, the method comprising administering to the patient two to four cookies two or three times daily.

6. The method of claim 4 , comprising administering to the patient two to four comestible units two or three times daily.

7. The method of claim 6 , wherein each comestible unit contains from 2,500 to 4,500 mg of inositol.

8. The method of claim 1 , wherein the therapeutically effective amount of inositol is up to 32,400 mg per day.

9. The method of claim 1 , wherein the therapeutically effective amount of inositol is from 15,000 mg to 32,400 mg per day.

10. The method of claim 1 , wherein the therapeutically effective amount of inositol is from 18,000 mg to 32,400 mg per day.

11. The method of claim 1 , wherein the therapeutically effective amount of inositol is from 18,000 mg to 32,400 mg per day, the plurality of inositol-containing comestible units are cookies and each cookie contains from 2,500 to 4,500 mg of inositol, the method comprising administering to the patient two to four cookies two or three times daily.

12. The method of claim 11 , wherein the method induces diarrhea in the patient and wherein the diarrhea is alleviated by reducing the amount of inositol administered to a maximum effective dose of inositol, the method providing a therapeutic effect which is not diminished at the maximum effective dose compared to a therapeutic effect the patient experienced when the method induced diarrhea in the patient.

13. The method of claim 1 , wherein the inositol-containing comestible units are baked goods, wherein the inositol in the plurality of inositol-containing comestible units does not have reduced therapeutic potency due to the inositol being exposed to high temperatures during baking, compared to an identical dose of inositol administered in raw powder form.

14. The method of claim 1 , wherein the inositol-containing comestible units are baked goods.

15. The method of claim 1 , wherein the therapeutically effective amount of inositol is from 18,000 mg to 32,400 mg per day, the plurality of inositol-containing comestible units are cookies, wherein each cookie contains from 2,500 to 4,500 mg of inositol, the method comprising administering to the patient two to four cookies two or three times daily.

16. The method of claim 1 , wherein the inositol in the plurality of inositol-containing comestible units does not have reduced therapeutic potency due to the inositol being exposed to high temperatures during the cooking or baking process, compared to an identical dose of inositol administered in raw powder form.

17. The method of claim 1 , wherein the inositol-containing comestible units are gummies or candies.

Continuity (5)
Continuation In Part 14596726 · Jan 14, 2015
Continuation In Part 14245121 · Apr 4, 2014
Continuation In Part 14166483 · Jan 28, 2014
Continuation In Part 13860824 · Apr 11, 2013
Related Publication 20170049715A1 · Feb 23, 2017